Impulsive and compulsive behaviors have become increasingly associated with Parkinson disease (PD) and treatment. Recently, the International Parkinson’s and Movement Disorder Society commissioned a task force to assess currently available screening tools and rating scales in order to make recommendations regarding their utility, as well as to inform future directions in scale development and validation.
Impulsive and compulsive behaviors (ICBs) have become increasingly associated with Parkinson disease (PD) and treatment. Recently, the International Parkinson’s and Movement Disorder Society commissioned a task force to assess currently available screening tools and rating scales in order to make recommendations regarding their utility, as well as to inform future directions in scale development and validation.
Members of the task force conducted a systematic review on available screening tools and scales used in PD studies to detect a range of impulse control disorders (ICDs), including compulsive medication use, pathological gambling, hypersexuality, binge eating, and reckless driving, among others.
The group identified 50 scales used to measure the severity of ICDs in studies of patients with PD. Study investigators assessed each scale for descriptive and clinometric properties, availability content, use, acceptability, and overall impression in patients with PD. The group recommended a scale if it had been applied to PD populations, contained data on the use of the scale in more than 1 cohort, and if the scale was determined as adequate for either screening purposes, assessing symptom severity, or measuring responsiveness to change.
The group reached a few recommendations on which scale to use:
The study authors suggest that early identification of ICDs can help guide treatment decisions in patients with PD, as the presence of multiple ICDs in this population may be associated with poorer quality of life, depression, or treatment resistance. Going forward, the researchers recommend that “further testing of established scales against gold standard diagnostic criteria is urgently required for all other individual ICBs in PD,” wrote the authors.
Reference
Evans A, Okai D, Weintraub D, et al. Members of the International Parkinson and Movement Disorder Society (IPMDS) rating scales review committee. Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: critique and recommendations. Mov Disord. 2019;34(6):791-798.
FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL
July 18th 2025The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Read More
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More